Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dermatology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 127 articles: HTML format

Single Articles

August 2024
1. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
   Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
   Cancer Lett. 2024;596:217001.
   PubMed     Abstract available
   
   
   
2. KIM YJ, Lee M, Kim EH, Lee S, et al
   Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
   Cancer Lett. 2024;596:216998.
   PubMed     Abstract available
   
   
   July 2024
3. LI M, Zhang L, Guan T, Huang L, et al
   Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
   Cancer Lett. 2024;595:216987.
   PubMed     Abstract available
   
   
   
4. LIU M, Zhao Z, Wang C, Sang S, et al
   Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
   Cancer Lett. 2024;594:216991.
   PubMed     Abstract available
   
   
   
5. FU Z, Zhang L, Chen R, Zhan J, et al
   Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
   Cancer Lett. 2024;598:217099.
   PubMed     Abstract available
   
   
   June 2024
6. LIAO Q, Shi H, Yang J, Ge S, et al
   FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
   Cancer Lett. 2024;592:216911.
   PubMed     Abstract available
   
   
   
7. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
   Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
   Cancer Lett. 2024;591:216879.
   PubMed     Abstract available
   
   
   May 2024
8. SONG Y, Ren S, Chen X, Li X, et al
   Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
   Cancer Lett. 2024;590:216847.
   PubMed     Abstract available
   
   
   
9. LV Y, Sun S, Zhang J, Wang C, et al
   Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
   Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
   PubMed     Abstract available
   
   
   
10. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    PubMed    
    
    
    
11. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    PubMed     Abstract available
    
    
    
12. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    PubMed     Abstract available
    
    
    April 2024
13. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    PubMed     Abstract available
    
    
    
14. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    PubMed     Abstract available
    
    
    
15. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    PubMed     Abstract available
    
    
    
16. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    PubMed     Abstract available
    
    
    
17. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    PubMed     Abstract available
    
    
    
18. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    PubMed     Abstract available
    
    
    
19. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    PubMed     Abstract available
    
    
    March 2024
20. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    PubMed     Abstract available
    
    
    
21. IDRISS MH, Stull CM, Migden MR
    Treatments on the horizon for locally advanced basal cell carcinoma.
    Cancer Lett. 2024;589:216821.
    PubMed     Abstract available
    
    
    
22. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    PubMed     Abstract available
    
    
    
23. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    PubMed     Abstract available
    
    
    February 2024
24. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    PubMed     Abstract available
    
    
    
25. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    PubMed     Abstract available
    
    
    
26. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    PubMed     Abstract available
    
    
    
27. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    PubMed     Abstract available
    
    
    
28. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    PubMed     Abstract available
    
    
    
29. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    Retraction notice to "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model" [Cancer Lett. 419 (2018) 30-39].
    Cancer Lett. 2024 Feb 2:216670. doi: 10.1016/j.canlet.2024.216670.
    PubMed     Abstract available
    
    
    
30. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    PubMed     Abstract available
    
    
    
31. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    PubMed     Abstract available
    
    
    January 2024
32. ZHANG J, Joshua AM, Yue L, O'Meara CH, et al
    Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
    Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633.
    PubMed     Abstract available
    
    
    
33. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    PubMed     Abstract available
    
    
    
34. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    PubMed     Abstract available
    
    
    
35. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    PubMed     Abstract available
    
    
    
36. LIU C, Cheng X, Han K, Hong L, et al
    A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
    Cancer Lett. 2024 Jan 19:216663. doi: 10.1016/j.canlet.2024.216663.
    PubMed     Abstract available
    
    
    
37. CHEN L, Xu G, Song X, Zhang L, et al
    A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Cancer Lett. 2024 Jan 16:216635. doi: 10.1016/j.canlet.2024.216635.
    PubMed     Abstract available
    
    
    December 2023
38. ZHONG W, Jian Y, Zhang C, Li Y, et al
    SHC4 orchestrates beta-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation.
    Cancer Lett. 2023 Dec 3:216516. doi: 10.1016/j.canlet.2023.216516.
    PubMed     Abstract available
    
    
    
39. LEI X, Liao R, Chen X, Wang Z, et al
    IMPA2 promotes basal-like breast cancer aggressiveness by a MYC-mediated positive feedback loop.
    Cancer Lett. 2023 Dec 2:216527. doi: 10.1016/j.canlet.2023.216527.
    PubMed     Abstract available
    
    
    November 2023
40. GUO H, Tan YQ, Huang X, Zhang S, et al
    Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.
    Cancer Lett. 2023;579:216443.
    PubMed     Abstract available
    
    
    
41. WU S, Lu J, Zhu H, Wu F, et al
    A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer.
    Cancer Lett. 2023;581:216508.
    PubMed     Abstract available
    
    
    
42. XIAO Q, Xia M, Tang W, Zhao H, et al
    The lipid metabolism remodeling: A hurdle in breast cancer therapy.
    Cancer Lett. 2023 Nov 28:216512. doi: 10.1016/j.canlet.2023.216512.
    PubMed     Abstract available
    
    
    
43. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    PubMed     Abstract available
    
    
    
44. HU X, Hu Z, Zhang H, Zhang N, et al
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Cancer Lett. 2023 Nov 7:216466. doi: 10.1016/j.canlet.2023.216466.
    PubMed     Abstract available
    
    
    September 2023
45. MORTAJA M, Demehri S
    Skin cancer prevention - Recent advances and unmet challenges.
    Cancer Lett. 2023 Sep 19:216406. doi: 10.1016/j.canlet.2023.216406.
    PubMed     Abstract available
    
    
    
46. XU M, Li S
    Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
    Cancer Lett. 2023 Sep 18:216397. doi: 10.1016/j.canlet.2023.216397.
    PubMed     Abstract available
    
    
    August 2023
47. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    PubMed     Abstract available
    
    
    July 2023
48. ZHANG X, Hu Z, Wang X, Li L, et al
    Corrigendum to "ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation" [Cancer Lett. 519 (2021) 237-249].
    Cancer Lett. 2023 Jul 18:216310. doi: 10.1016/j.canlet.2023.216310.
    PubMed    
    
    
    
49. TER STEEGE EJ, Doornbos LW, Haughton PD, van Diest PJ, et al
    R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling.
    Cancer Lett. 2023 Jul 3:216301. doi: 10.1016/j.canlet.2023.216301.
    PubMed     Abstract available
    
    
    May 2023
50. REN Z, Xue Y, Liu L, Zhang X, et al
    Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
    Cancer Lett. 2023 May 14:216221. doi: 10.1016/j.canlet.2023.216221.
    PubMed     Abstract available
    
    
    March 2023
51. ZHAO J, Gao N, Xu J, Zhu X, et al
    Novel strategies in melanoma treatment using silver nanoparticles.
    Cancer Lett. 2023 Mar 27:216148. doi: 10.1016/j.canlet.2023.216148.
    PubMed     Abstract available
    
    
    
52. ZHANG Y, Chen J, Mi D, Ling J, et al
    Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway.
    Cancer Lett. 2023;560:216142.
    PubMed     Abstract available
    
    
    
53. DENG L, Liao L, Zhang YL, Hu SY, et al
    MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Cancer Lett. 2023 Mar 10:216124. doi: 10.1016/j.canlet.2023.216124.
    PubMed     Abstract available
    
    
    
54. MA J, Zhu J, Li J, Liu J, et al
    Enhanced E6AP-mediated ubiquitination of ENO1 via LINC00663 contributes to radiosensitivity of breast cancer by regulating mitochondrial homeostasis.
    Cancer Lett. 2023 Mar 3:216118. doi: 10.1016/j.canlet.2023.216118.
    PubMed     Abstract available
    
    
    February 2023
55. BERG AL, Showalter MR, Kosaisawe N, Hu M, et al
    Cellular transformation promotes the incorporation of docosahexaenoic acid into the endolysosome-specific lipid bis(monoacylglycerol)phosphate in breast cancer.
    Cancer Lett. 2023;557:216090.
    PubMed     Abstract available
    
    
    
56. GANDULLO-SANCHEZ L, Pandiella A
    An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
    Cancer Lett. 2023;554:216024.
    PubMed     Abstract available
    
    
    January 2023
57. WANG L, Mi D, Hu J, Liu W, et al
    A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.
    Cancer Lett. 2023;555:216049.
    PubMed     Abstract available
    
    
    December 2022
58. DENG S, Banerjee S, Chen H, Pochampally S, et al
    SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Cancer Lett. 2022 Dec 31:216046. doi: 10.1016/j.canlet.2022.216046.
    PubMed     Abstract available
    
    
    
59. LEE Y, Graham P, Li Y
    Extracellular vesicles as a novel approach for breast cancer therapeutics.
    Cancer Lett. 2022 Dec 12:216036. doi: 10.1016/j.canlet.2022.216036.
    PubMed     Abstract available
    
    
    October 2022
60. DU Y, Cai Y, Lv Y, Zhang L, et al
    Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma.
    Cancer Lett. 2022 Oct 17:215972. doi: 10.1016/j.canlet.2022.215972.
    PubMed     Abstract available
    
    
    
61. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
    Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
    Cancer Lett. 2022;546:215850.
    PubMed     Abstract available
    
    
    
62. XIE XF, Wu NQ, Wu JF, Zhang GL, et al
    CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944.
    PubMed     Abstract available
    
    
    
63. LUO Y, Tang W, Xiang S, Feng J, et al
    Non-coding RNAs in breast cancer: Implications for programmed cell death.
    Cancer Lett. 2022 Oct 3:215929. doi: 10.1016/j.canlet.2022.215929.
    PubMed     Abstract available
    
    
    
64. HUANG CP, Liu LC, Chang CC, Wu CC, et al
    Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.
    Cancer Lett. 2022;545:115478.
    PubMed     Abstract available
    
    
    September 2022
65. LUO M, Li J, Yang Q, Xu S, et al
    N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation.
    Cancer Lett. 2022 Sep 23:215926. doi: 10.1016/j.canlet.2022.215926.
    PubMed     Abstract available
    
    
    
66. LI T, Zhai D, Zhang M, Ye R, et al
    KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis.
    Cancer Lett. 2022 Sep 8:215904. doi: 10.1016/j.canlet.2022.215904.
    PubMed     Abstract available
    
    
    
67. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    PubMed     Abstract available
    
    
    August 2022
68. ZHANG T, Huang P
    Response to letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Cancer Lett. 2022 Aug 23:215881. doi: 10.1016/j.canlet.2022.215881.
    PubMed    
    
    
    
69. WANG M, Wei R, Li G, Bi HL, et al
    SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission.
    Cancer Lett. 2022 Aug 20:215871. doi: 10.1016/j.canlet.2022.215871.
    PubMed     Abstract available
    
    
    
70. WANG Y, Zhou X, Lei Y, Chu Y, et al
    NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity.
    Cancer Lett. 2022;547:215884.
    PubMed     Abstract available
    
    
    
71. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    PubMed     Abstract available
    
    
    
72. LIANG Y, Zhou X, Xie Q, Sun H, et al
    CD146 interaction with integrin beta1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells.
    Cancer Lett. 2022;546:215856.
    PubMed     Abstract available
    
    
    July 2022
73. DU Z, Feng Y, Zhang H, Liu J, et al
    Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation.
    Cancer Lett. 2022 Jul 31:215841. doi: 10.1016/j.canlet.2022.215841.
    PubMed     Abstract available
    
    
    
74. RODRIGUES-FERREIRA S, Nahmias C
    Predictive biomarkers for personalized medicine in breast cancer.
    Cancer Lett. 2022;545:215828.
    PubMed     Abstract available
    
    
    
75. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth.
    Cancer Lett. 2022 Jul 5:215800. doi: 10.1016/j.canlet.2022.215800.
    PubMed     Abstract available
    
    
    June 2022
76. ZHAI D, Zhang M, Li Y, Bi J, et al
    LINC01194 recruits NUMA1 to promote ubiquitination of RYR2 to enhance malignant progression in triple-negative breast cancer.
    Cancer Lett. 2022 Jun 21:215797. doi: 10.1016/j.canlet.2022.215797.
    PubMed     Abstract available
    
    
    
77. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    PubMed     Abstract available
    
    
    May 2022
78. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    PubMed     Abstract available
    
    
    
79. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    PubMed     Abstract available
    
    
    
80. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    PubMed     Abstract available
    
    
    
81. LAURIN KM, Coutu-Beaudry K, Salazar A, Meribout N, et al
    Low expression of PGC-1beta and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1.
    Cancer Lett. 2022 May 17:215738. doi: 10.1016/j.canlet.2022.215738.
    PubMed     Abstract available
    
    
    
82. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    PubMed     Abstract available
    
    
    
83. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    PubMed     Abstract available
    
    
    April 2022
84. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    PubMed     Abstract available
    
    
    March 2022
85. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    PubMed     Abstract available
    
    
    
86. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    PubMed     Abstract available
    
    
    
87. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    PubMed     Abstract available
    
    
    
88. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    PubMed     Abstract available
    
    
    February 2022
89. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available
    
    
    January 2022
90. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    PubMed     Abstract available
    
    
    
91. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    PubMed     Abstract available
    
    
    
92. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    PubMed     Abstract available
    
    
    
93. HOUBEN R, Hesbacher S, Sarma B, Schulte C, et al
    Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
    Cancer Lett. 2022;524:259-267.
    PubMed     Abstract available
    
    
    
94. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    PubMed     Abstract available
    
    
    
95. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    PubMed     Abstract available
    
    
    December 2021
96. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    PubMed     Abstract available
    
    
    
97. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    PubMed     Abstract available
    
    
    
98. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    PubMed     Abstract available
    
    
    November 2021
99. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    PubMed     Abstract available
    
    
    
100. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
     A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
     Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
     PubMed     Abstract available
     
     
     
101. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
     Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
     Cancer Lett. 2021;520:374-384.
     PubMed     Abstract available
     
     
     
102. LEE O, Bosland MC, Wang M, Shidfar A, et al
     Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
     Cancer Lett. 2021;520:255-266.
     PubMed     Abstract available
     
     
     October 2021
103. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
     Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
     Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
     PubMed     Abstract available
     
     
     
104. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
     Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
     Cancer Lett. 2021;517:24-34.
     PubMed     Abstract available
     
     
     September 2021
105. XIA M, Zu X, Chen Z, Wen G, et al
     Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
     Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
     PubMed     Abstract available
     
     
     
106. LI C, Qiu S, Jin K, Zheng X, et al
     Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
     Cancer Lett. 2021;523:43-56.
     PubMed     Abstract available
     
     
     
107. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
     SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
     Cancer Lett. 2021;522:211-224.
     PubMed     Abstract available
     
     
     August 2021
108. ZHANG M, Liu J, Liu G, Xing Z, et al
     Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
     Cancer Lett. 2021 Aug 10. pii: S0304-3835(21)00394.
     PubMed     Abstract available
     
     
     
109. NYATI KK, Hashimoto S, Singh SK, Tekguc M, et al
     The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
     Cancer Lett. 2021;520:295-306.
     PubMed     Abstract available
     
     
     
110. ZHU Y, Zhang H, Han X, Wang Z, et al
     STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.
     Cancer Lett. 2021 Aug 1. pii: S0304-3835(21)00380.
     PubMed     Abstract available
     
     
     July 2021
111. MCGARRY DJ, Armstrong G, Castino G, Mason S, et al
     MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.
     Cancer Lett. 2021 Jul 24. pii: S0304-3835(21)00371.
     PubMed     Abstract available
     
     
     
112. PENUGURTI V, Khumukcham SS, Padala C, Dwivedi A, et al
     HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways.
     Cancer Lett. 2021;518:243-255.
     PubMed     Abstract available
     
     
     
113. PETRI BJ, Piell KM, South Whitt GC, Wilt AE, et al
     HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
     Cancer Lett. 2021;518:152-168.
     PubMed     Abstract available
     
     
     
114. XU X, Li N, Wang Y, Yu J, et al
     Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.
     Cancer Lett. 2021;519:150-160.
     PubMed     Abstract available
     
     
     
115. MININI M, Senni A, He X, Proietti S, et al
     miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting.
     Cancer Lett. 2021 Jul 3. pii: S0304-3835(21)00326.
     PubMed     Abstract available
     
     
     June 2021
116. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
     Fibronectin regulates anoikis resistance via cell aggregate formation.
     Cancer Lett. 2021;508:59-72.
     PubMed     Abstract available
     
     
     
117. SANG X, Li L, Rui C, Liu Y, et al
     Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
     Cancer Lett. 2021;518:82-93.
     PubMed     Abstract available
     
     
     
118. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
     Transgenic mouse models of breast cancer.
     Cancer Lett. 2021;516:73-83.
     PubMed     Abstract available
     
     
     May 2021
119. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
     Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
     Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
     PubMed     Abstract available
     
     
     
120. WANG H, Shi Y, Chen CH, Wen Y, et al
     KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
     Cancer Lett. 2021;515:49-62.
     PubMed     Abstract available
     
     
     
121. LI X, Wang H, Yang X, Wang X, et al
     GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
     Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
     PubMed     Abstract available
     
     
     
122. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
     Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
     Cancer Lett. 2021;514:12-29.
     PubMed     Abstract available
     
     
     
123. LIGORIO F, Pellegrini I, Castagnoli L, Vingiani A, et al
     Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
     Cancer Lett. 2021 May 4. pii: S0304-3835(21)00189.
     PubMed     Abstract available
     
     
     
124. WANG M, Dai M, Wang D, Tang T, et al
     The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway.
     Cancer Lett. 2021 May 2. pii: S0304-3835(21)00191.
     PubMed     Abstract available
     
     
     April 2021
125. VENKATESH J, Wasson MD, Brown JM, Fernando W, et al
     LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
     Cancer Lett. 2021 Apr 10. pii: S0304-3835(21)00156.
     PubMed     Abstract available
     
     
     
126. WANG CJ, Li D, Danielson JA, Zhang EH, et al
     Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
     Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
     PubMed     Abstract available
     
     
     March 2021
127. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
     Contribution of the tumor and obese microenvironment to triple negative breast cancer.
     Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.